These findings demonstrate that BRACs inhibit the metastasis of HER-2–positive breast cancer in vitro and that the Src/FAK/p130Cas signaling pathway plays an important role in these inhibitory effects of BRACs. Here, PTK2 is linked to breast carcinoma.